College Call Girls in Haridwar 9667172968 Short 4000 Night 10000 Best call gi...
Anticoagulants for Acute Coronary Syndromes
1. Anticoagulants in
Acute Coronary Syndrome
LHH Cardiology Grand Rounds
March 11th
2014
Salaheldin Abusin
Interventional Cardiology Fellow
2. Outline
• Review the Historical Evidence for use of
anticoagulants in secondary prevention after ACS
(pre DAPT era)
• Review the Evidence for the use of novel
anticoagulants as third agent in addition to DAPT
– Apixaban – APPRAISE trial
– Dabigatran – REDEEM trial
– Rivoraxaban – ATLAS ACS TIMI 58 trial
6. Aspirin + warfarin after ACS
CHAMP trial
• N= 5059
• Randomized, Open Label
• Patient within 14 days of Acute MI
• 2:3, STEMI/NSTEMI
• 1st
arm Warfarin (target INR 1.5-2.5) + ASA 81mg
• 2nd
arm ASA 325mg
• Followed up for 2.7 years
Fiori et al, Circulation 2002
7. CHAMP Trial Results
• No difference in the 1° endpoint (mortality)
• 17.3% vs 17.6%, P=0.76
• Major Bleeding significantly higher in the
warfarin arm
– 1.28 events / 100 person years vs
– 0.72 events/ 100 person years
– P <0.001
10. Aspirin + Ximelagatran after ACS
ESTEEM trial – Phase 2 trial
• N=1883
• Within 14 days of STEMI/NSTEMI (2:1)
• All patients were on aspirin 160mg
• Dose finding trial
• 24mg/36mg/48mg/60mg/Placebo
• Primary Endpoint Death/MI/recurrent
ischemia
Wallentin et al, Lancet 2003
11. Aspirin + Ximelagatran after ACS
ESTEEM trial – Phase 2 trial
• Followed for 6 months
• MACE Primary Endpoint
– 12.7% vs 16.3% (P=0.036) at 6 months
– ARR 3.6%, NNT = 27
– Not dose dependant
• Major Bleeding
– 1.8% vs 0.9% (not significant statistically)
• Hepatotoxicity halted the further
development of this agent
12. Clopidogrel
CURE
Clopidogrel
CURE
AHA.ACC 2007
Guidelines
Establish DAPT
as standard of
care for ACS
AHA.ACC 2007
Guidelines
Establish DAPT
as standard of
care for ACS
Prasugrel
TRITON
TIMI 38
Prasugrel
TRITON
TIMI 38
Ticagrelor
PLATO
Ticagrelor
PLATO
Warfarin
CHAMP trial
Warfarin
CHAMP trial
Dabigatran
RE-DEEM trial
Dabigatran
RE-DEEM trial
Apixaban
APPRAISE trial
Apixaban
APPRAISE trial
Rivoroxaban
ATLAS ACS
TIMI 51
trial
Rivoroxaban
ATLAS ACS
TIMI 51
trial
Ximelagatran
ESTEEM trial
Ximelagatran
ESTEEM trial
Clopidogrel
CREDO
Clopidogrel
CREDO
13. Things to consider
• The need for a 3rd
agent beyond DAPT for ACS
• Risk of Ischemic Events
– ~ 10% risk of ischemic events
– ~3% risk of death from cardiovascular cause
• Risk of Bleeding Events
– ~2% risk of bleeding
– 0.3% risk of fatal bleeding
• Any 3rd
agent needs to prove efficacy and safety
15. Dabigatran (Pradaxa)
• Direct Thrombin Inhibitor
• Approved for
– Stroke Prevention in non valvular A fib
– First of the 3 FDA approved novel anticoagulants
• RELY trial, NEJM, 2009
• 150mg BID for normal renal function
• 75mg BID for impaired renal function
• Although 110mg BID was the safer dose
– Prevention of DVT in hip/knee surgery
16. DAPT + Dabigatran after ACS
REDEEM trial – Phase 2 trial
• Phase II Trial
• Dose finding
• Randomized, Double Blind Trial
• N=1861
• Within 7days of STEMI/NSTEMI (60%/40%)
Oldgren et al, EHJ 2011
17. DAPT + Dabigatran after ACS
REDEEM trial – Phase 2 trial
• All patients were on DAPT
– Aspirin & Clopidogrel
• Dabigatran (Dose Escalation Randomization)
– 50mg BID, 75mg BID (first stage)
– 110 mg BID (second stage)
– 150mg BID (third stage)
• Placebo
• Followed for 6 months
Oldgren et al, EHJ 2011
18.
19. DAPT + Dabigatran after ACS
REDEEM trial – Phase 2 trial
• Safety Trial
• Composite Endpoint of Primary Endpoint
– Major Bleeding (ISTH definition)
• Critical location (eyes, brain, joints, retroperitoneal,
pericardial)
• >= 2gm/dl drop in Hb
• Transfusion 2 or more units
– Clinically relevant minor bleeding
• Overt bleeding less than major bleeding
• Prompted a clinical response (hospital admission,
additional medical/surgical treatment, change in ttt)
20. Clopidogrel
CURE
Clopidogrel
CURE
AHA.ACC 2007
Guidelines
Establish DAPT
as standard of
care for ACS
AHA.ACC 2007
Guidelines
Establish DAPT
as standard of
care for ACS
Prasugrel
TRITON
TIMI 38
Prasugrel
TRITON
TIMI 38
Ticagrelor
PLATO
Ticagrelor
PLATO
Warfarin
CHAMP trial
Warfarin
CHAMP trial
Dabigatran
RE-DEEM trial
Dabigatran
RE-DEEM trial
Apixaban
APPRAISE trial
Apixaban
APPRAISE trial
Rivoroxaban
ATLAS ACS
TIMI 51
trial
Rivoroxaban
ATLAS ACS
TIMI 51
trial
Ximelagatran
ESTEEM trial
Ximelagatran
ESTEEM trial
Clopidogrel
CREDO
Clopidogrel
CREDO
22. Apixaban(Eliquis)
• Direct Factor Xa Inhibitor
• Approved for
– Stroke Prevention in non valvular A fib
– 3rd
agent to get approved from the novel anticoagulants
• ARITSTOTLE trial, NEJM, 2011
• 5mg BID for normal renal function
• 2.5mg BID for impaired renal function, low weight, >80
23. DAPT + Apixaban after ACS
APPRAISE trial
• Randomized, Double Blind Trial
• N=7392
• Within 7days of STEMI/NSTEMI (40%/60%)
• Additional 2 risk factors
– Previous MI, Low EF, Impaired renal function
– DM, CVA, PAD
• Followed for ~ 8 months
Alexander et al, NEJM 2011
24. DAPT + Apixaban after ACS
APPRAISE trial
• All patients were on DAPT (Aspirin & Clopidogrel)
• Apixaban 5mg BID vs Placebo
• Composite Primary Endpoint
– MACCE (CV Death, MI, Ischemic Stroke)
• Primary Safety Outcome
– TIMI Bleeding definition
– Major Bleeding (IC Bleeding, bleeding with > 5g/dl
drop, fatal bleeding)
30. Rivoraxaban (Xarelto)
• Direct Factor Xa Inhibitor
• Stroke Prevention in non valvular A fib
• 2nd
agent to get approved from the novel anticoagulants
• ROCKET AF trial, NEJM, 2011 (non inferior)
• 20mg once daily for normal renal function
• 15mg once daily for impaired renal function
• prevention of DVT in knee/hip replacement
• Treatment for DVT & PE &
• Prevention of recurrence DVT/PE
32. DAPT + Rivaroxaban after ACS
ATLAS ACS TIMI 51 trial
• Randomized, Double Blind Trial
• N=15,526
• Within 5 days of ACS
– STEMI 50%
– NSTEMI 25%
– USA 25%
• >55 or
• < 55 + DM or previous MI
Mega et al, NEJM 2012
33. Excluded
• Plat <90,000
• PH of ICH
• PH of TIA/Stroke on DAPT
• Significant GI bleeding in last 12 months
• Hb < 10
• Cr Cl <30ml/min
34. • All patients were on DAPT (Aspirin & Clopidogrel)
• 3 arms
– Rivoraxaban 5mg BID
– Rivoraxaban 2.5mg BID
– Placebo
• Followed for 13 months
35. Baseline Characteristics
• Average patient was a 62 yo, 80 kg, white, male
• Normal renal function
• 1/3 DM, 2/3 HTN, ½ dyslipidemia, ¼ previous MI
• Region
– 40% Eastern Europe
– 21% Asian
– 13.7% Western Europe
– 5% North America
39. 2.5mg 5mg Placebo
CV Death 2.7% 4.0% 4.1%
Fatal Bleeding 0.1% 0.4% 0.2%
Any Death 2.9% 4.4% 4.5%
Death
• NNT to save 1 life (from CV death) = 71
• NNT to save 1 life (any death) = 63
40. Ischemic Endpoints
MI, Ischemic Stroke, ST
• NNT to prevent 1 MI (5mg) = 59
• NNT to prevent 1 ST = 143
2.5mg 5mg Placebo
Non fatal MI 6.1% 4.9% 6.6%
Ischemic Stroke 1.0% 0.9% 1.0%
Stent
thrombosis
2.2% 2.3% 2.9%
41. Bleeding Endpoints
• NNH to cause one major bleed (2.5mg) = 83
• NNH to cause one ICH bleeding (2.5mg) = 500
2.5mg 5mg Placebo
Major Bleeding 1.8% 2.4% 0.6%
ICH 0.4% 0.7% 0.2%
42. If you use 5mg BID Rivoraxaban as
3rd
Agent
• No significant reduction in death (whatever
type)
• Treat 59 patients to prevent 1 non fatal MI
• Treat 167 patients to prevent 1 ST
• Treat 55 patients to get 1 major bleed
• Treat 200 patients to get 1 ICH
• Not favorable
43. If you use 2.5mg BID Rivoraxaban
as 3rd
Agent
• Treat 71 patients to prevent 1 death
• Treat 143 patients to prevent 1 ST
• Treat 88 patients to get 1 major bleed
• Treat 590 patients to get 1 ICH
• OK result
44. Finding the sweet spot
• Subanalysis of patients with STEMI revealed a
mortality benefit
• 2.5mg BID 2.5%
• Placebo 4.2%
• ARR 1.7%, NNT 59
Mega et al, JACC 2013
46. Finding the sweet spot
• Subanalysis of patients who received stents
for ACS revealed a reduction in Stent
thrombosis
• 2.5mg BID 1.9%
• Placebo 1.5%
• ARR 0.4%, NNT 250
Gibson et al, JACC 2013
48. What we learnt
• Novel anticoagulants generally don’t work as 3rd
agent add on to DAPT due to prohibitive
bleeding risk
• Unless you give it in patients with
– Low risk of bleeding
– At very low dose ( Rivaroxaban 2.5mg BID)
– Especially after STEMI, and those who undergo PCI
– Still have to deal with the risk of a major bleed